The GMRF Clinical Trials Unit is currently recruiting for the following clinical trials in Haematology:

Protocol: C1071005 (PI: Dr Anthony Mills) (not yet recruiting)

Protocol Title: An Open-Label, 3-Arm, Multicenter, Randomized Phase 3 Study to evaluate the Efficacy and Safety of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab versus Daratumumab + Pomalidomide + Dexamethasone in participants with Relapsed/Refractory Multiple Myeloma who have received at least 2 prior lines of therapy including Lenalidomide and a Proteasome Inhibitor

Lay Title: MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

Click here for more information

Protocol: MoR208C310 (PI: Dr Anthony Mills)

Protocol Title: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to compare the efficacy and safety of the humanized monoclonal anti CD19 antibody tafasitamab plus lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed DLBCL

Lay Title: Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

Click here for more information